Compare
Vaxcyte, Inc. vs Repligen Corp vs Exelixis, Inc. vs Halozyme Therapeutics, Inc.
| Latest fiscal year | Vaxcyte, Inc. PCVX | Repligen Corp RGEN | Exelixis, Inc. EXEL | Halozyme Therapeutics, Inc. HALO |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2025-12-31 | 2026-01-02 | 2025-12-31 |
| Revenue | n/a | $738.26M | $2.32B | $1.40B |
| Revenue growth (YoY) | n/a | +16.4% | +7.0% | +37.6% |
| Gross margin | n/a | 52.3% (computed) | n/a | 83.6% (computed) |
| Operating margin | n/a | 7.5% | 37.6% | 33.6% |
| Net margin | n/a | 6.6% | 33.7% | 22.7% |
| Net income | -$766.63M | $48.89M | $782.57M | $316.89M |
| EPS (Diluted) | -$5.63 | $0.86 | $2.78 | $2.56 |
| Operating cash flow | -$655.58M | $117.42M | $884.27M | $651.56M |
| Free cash flow | -$669.29M | $93.90M | $875.84M | $644.59M |
| Cash & equivalents | $173.96M | $566.02M | $482.49M | $133.82M |
| Total assets | $3.00B | $2.95B | $2.84B | $2.53B |
| Total liabilities | $317.21M | $843.57M | $683.10M | $2.48B |
| Shareholders' equity | $2.69B | $2.11B | $2.16B | $48.81M |
| Return on year-end equity | -28.5% | 2.3% | 36.2% | 649.2% |
| Shares outstanding | 131.06M | 56.33M | 262.48M | 117.78M |
Revenue, most recent five fiscal years
| Fiscal year | Vaxcyte, Inc. | Repligen Corp | Exelixis, Inc. | Halozyme Therapeutics, Inc. |
|---|---|---|---|---|
| Latest | n/a | $738.26M Ended 2025-12-31 | $2.32B Ended 2026-01-02 | $1.40B Ended 2025-12-31 |
| 1 year earlier | n/a | $634.44M Ended 2024-12-31 | $2.17B Ended 2025-01-03 | $1.02B Ended 2024-12-31 |
| 2 years earlier | n/a | $632.36M Ended 2023-12-31 | $1.83B Ended 2023-12-29 | $829.25M Ended 2023-12-31 |
| 3 years earlier | n/a | $801.54M Ended 2022-12-31 | $1.61B Ended 2022-12-30 | $660.12M Ended 2022-12-31 |
| 4 years earlier | n/a | $670.53M Ended 2021-12-31 | $1.43B Ended 2021-12-31 | $443.31M Ended 2021-12-31 |